Novo
-
Australia
Novo Nordisk to sell Wegovy weight-loss pill in US
Danish drugmaker Novo Nordisk is launching the once-daily Wegovy pill in the United States. It is offering 1.5-milligram and 4-mg…
Read More » -
Australia
Novo Nordisk to sell Wegovy weight-loss pill in US
6 January 2026 00:08 | News Danish drugmaker Novo Nordisk is launching the once-daily Wegovy pill in the United States.…
Read More » -
USA
Novo Nordisk to sell Wegovy pill to US self-pay patients starting at $149 per month
COPENHAGEN, Jan 5 (Reuters) – Denmark’s Novo Nordisk said on Monday it will offer 1.5- and 4-milligram Wegovy weight-loss pills…
Read More » -
USA
Novo Nordisk faces ‘must-win’ battle over U.S. Wegovy, Ozempic in 2026
Still life of three major injectable prescription weight loss drugs. Ozempic, Victoza and Wegovy. (Photo: Michael Siluk/UCG/Universal Images Group via…
Read More » -
USA
Novo and Lilly cut prices of weight-loss drugs in China
Reuters Videos Tue, 30 December 2025 19:08 GMT+8 STORY: Novo Nordisk and Eli Lilly are cutting prices of best-selling obesity…
Read More » -
USA
Novo Nordisk beyond weight loss has investors wary, scientists hopeful
Ozempic is a medication for adults with type 2 diabetes that, along with diet and exercise, can improve blood sugar.…
Read More » -
USA
Wegovy-maker Novo Nordisk shares surge after GLP-1 pill approval
Shares of Novo Nordisk rose 6% on Tuesday after the Wegovy maker received approval for its world-first GLP-1 pill. The…
Read More » -
USA
FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd on the outskirts of…
Read More » -
USA
Obesity pills from Novo Nordisk, Eli Lilly are coming
Daniel Grill | Tetra Pictures | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter,…
Read More » -
USA
Why Medicare price cuts matter for Novo Nordisk, European pharma
Drug pricing has emerged as an important issue for pharmaceutical companies and investors to pay attention to in 2025. As…
Read More »
